129 related articles for article (PubMed ID: 34787423)
21. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.
Johnson CW; Lin YJ; Reid D; Parker J; Pavlopoulos S; Dischinger P; Graveel C; Aguirre AJ; Steensma M; Haigis KM; Mattos C
Cell Rep; 2019 Aug; 28(6):1538-1550.e7. PubMed ID: 31390567
[TBL] [Abstract][Full Text] [Related]
22. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
23. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
[TBL] [Abstract][Full Text] [Related]
25. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
26. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.
Burns MC; Sun Q; Daniels RN; Camper D; Kennedy JP; Phan J; Olejniczak ET; Lee T; Waterson AG; Rossanese OW; Fesik SW
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3401-6. PubMed ID: 24550516
[TBL] [Abstract][Full Text] [Related]
27. SPROUT: recent developments in the de novo design of molecules.
Gillet VJ; Newell W; Mata P; Myatt G; Sike S; Zsoldos Z; Johnson AP
J Chem Inf Comput Sci; 1994; 34(1):207-17. PubMed ID: 8144711
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors.
Hussain J; Chhabria D; Kirubakaran S
Bioorg Med Chem Lett; 2020 Aug; 30(16):127290. PubMed ID: 32631512
[TBL] [Abstract][Full Text] [Related]
29. Targeting oncogenic transcriptional corepressor Nac1 POZ domain with conformationally constrained peptides by cyclization and stapling.
Wu T; He P; Wu W; Chen Y; Lv F
Bioorg Chem; 2018 Oct; 80():1-10. PubMed ID: 29864683
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target.
Adeniji EA; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2018; 18(11):1540-1550. PubMed ID: 30019652
[TBL] [Abstract][Full Text] [Related]
31. Progress in targeting RAS with small molecule drugs.
McCormick F
Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
[TBL] [Abstract][Full Text] [Related]
32. [Conformational aspects of biological activity of functional fragments of the p21ras oncoproteins. 3. Fragment 34-46 of the native oncoprotein and the decapeptide corresponding to its 35-44 sequence].
Mzareulov KD
Bioorg Khim; 2003; 29(4):361-72. PubMed ID: 12947757
[TBL] [Abstract][Full Text] [Related]
33. Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System.
Röth S; Macartney TJ; Konopacka A; Chan KH; Zhou H; Queisser MA; Sapkota GP
Cell Chem Biol; 2020 Sep; 27(9):1151-1163.e6. PubMed ID: 32668202
[TBL] [Abstract][Full Text] [Related]
34. Structure-based derivation and optimization of YAP-like coactivator-derived peptides to selectively target TEAD family transcription factors by hydrocarbon stapling and cyclization.
He B; Wu T; He P; Lv F; Liu H
Chem Biol Drug Des; 2021 Jun; 97(6):1129-1136. PubMed ID: 33283479
[TBL] [Abstract][Full Text] [Related]
35. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Chen H; Smaill JB; Liu T; Ding K; Lu X
J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
[TBL] [Abstract][Full Text] [Related]
36. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
[TBL] [Abstract][Full Text] [Related]
37. KRAS Alleles: The Devil Is in the Detail.
Haigis KM
Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
[TBL] [Abstract][Full Text] [Related]
38. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.
Evelyn CR; Biesiada J; Duan X; Tang H; Shang X; Papoian R; Seibel WL; Nelson S; Meller J; Zheng Y
J Biol Chem; 2015 May; 290(20):12879-98. PubMed ID: 25825487
[TBL] [Abstract][Full Text] [Related]
39. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Tanada M; Tamiya M; Matsuo A; Chiyoda A; Takano K; Ito T; Irie M; Kotake T; Takeyama R; Kawada H; Hayashi R; Ishikawa S; Nomura K; Furuichi N; Morita Y; Kage M; Hashimoto S; Nii K; Sase H; Ohara K; Ohta A; Kuramoto S; Nishimura Y; Iikura H; Shiraishi T
J Am Chem Soc; 2023 Aug; 145(30):16610-16620. PubMed ID: 37463267
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology.
Garrigou M; Sauvagnat B; Duggal R; Boo N; Gopal P; Johnston JM; Partridge A; Sawyer T; Biswas K; Boyer N
J Med Chem; 2022 Jul; 65(13):8961-8974. PubMed ID: 35707970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
